Welcome to our dedicated page for Charles River Laboratories International news (Ticker: $CRL), a resource for investors and traders seeking the latest updates and insights on Charles River Laboratories International stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Charles River Laboratories International's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Charles River Laboratories International's position in the market.
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) collaborates with National University of Singapore’s Yong Loo Lin School of Medicine to provide phase-appropriate plasmid DNA for cancer therapy. This partnership aims to support the development of engineered stem cells for cancer treatment, leveraging Charles River's expertise in HQ and GMP-compliant plasmid DNA manufacturing. The collaboration will utilize Charles River’s eXpDNA™ platform to enhance NUS Medicine's research capabilities in stem cell biology and therapy, offering a complete solution from concept to cure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
-
Rhea-AI Summary
Charles River Laboratories and Navega Therapeutics announce an AAV9 production program agreement to develop a non-opioid gene therapy, NT-Z001, for chronic pain disorders. Navega's AI-enabled zinc-finger epigenome regulation platform targets rare diseases like small fiber neuropathy and primary erythromelalgia, addressing a gain-of-function mutation in the Nav 1.7 gene. With over 17 million Americans suffering from chronic pain, this therapy shows promise for various pain indications. Charles River's CGT Accelerator Program supports Navega's efforts by providing CDMO solutions and advisory services to expedite clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (CRL) will present at the Barclays 26th Annual Global Healthcare Conference, discussing strategic focus, business developments, and recent trends. The webcast will be available on their Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
Rhea-AI Summary
Wheeler Bio, Inc. partners with Charles River Laboratories International, Inc. to offer Portable CMC® platform, aiming to streamline therapeutic discovery and accelerate IND submission timelines. The collaboration combines expertise in antibody discovery, safety, and analytics to simplify the development process and provide a comprehensive concept-to-commercial offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (CRL) announces a strategic agreement with Wheeler Bio, Inc. to provide early-stage biotech companies with access to Wheeler's Portable CMC® platform, accelerating therapeutic discovery timelines. This collaboration aims to streamline preclinical to clinical manufacturing processes, reducing vendor complexities and integrating CMC development early in discovery. Wheeler's mission is to solve translational challenges in advancing from discovery to CMC development and early-clinical trial material supply.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
-
News
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) has partnered with Pluristyx Inc. to expand its stem cell research tools, including high-quality embryonic stem cells and induced pluripotent stem cells. The collaboration aims to accelerate therapeutic development by providing researchers with advanced cell lines and technologies for new therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
Rhea-AI Summary
Charles River Laboratories International, Inc. (CRL) reports fourth-quarter revenue of $1.01 billion, full-year revenue of $4.13 billion, with GAAP earnings per share of $3.62 and non-GAAP earnings per share of $2.46. The company provided 2024 guidance, anticipating a cautious biopharmaceutical demand environment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.3%
Tags
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) has launched the Endosafe® Trillium™ rCR cartridge offering, an animal-free testing solution that enhances testing efficiency and accelerates manufacturing timelines. This innovation builds upon the company's flagship Endosafe® cartridge technology and their recombinant cascade reagent (rCR) to bolster commitments to sustainability and animal welfare.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) has appointed Reshema Kemps-Polanco, Executive Vice President and Chief Commercial Officer of Novartis US, to its Board of Directors. With 25 years of experience in the pharmaceutical industry, Ms. Kemps-Polanco will bring valuable insights and knowledge to Charles River's Board. Her extensive experience in leading commercial organizations and her commitment to improving patient access and health outcomes will greatly benefit Charles River's growth strategy. As a member of the Board, she will serve on the Compensation and Strategic Planning and Capital Allocation Committees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.04%
Tags
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) is set to release its fourth-quarter and full-year 2023 financial results and provide 2024 guidance on February 14th. A conference call will be held at 8:30 a.m. ET on the same day to discuss the information. Investors can listen to a live webcast through the Company's website and access a replay afterward.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
Charles River Laboratories International, Inc.
NYSE:CRL
CRL Rankings
CRL Stock Data
11.75B
50.74M
0.98%
103.03%
3.08%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
United States of America
WILMINGTON
About CRL
charles river provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. #drugdiscovery #biotech #biotechnology #pharmaceuticals #cro